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Stroke is the number one cause of disability in the USA;
despite remarkable advancements in the primary and
secondary prevention of stroke, over five million Americans
(and many more of our brethren around the world) possess
significant limitations in their ability to lead a quality life as a
result of stroke [1]. Patients of mine who expected to retire
to lives of playing golf and chasing their grandchildren
instead are often relegated to a sedentary and more isolated
existence. These clinical examples represent only the tip of
the iceberg of the handicap and suffering that develops too
often following stroke. It is thus surprising that unlike the
treatment of cancer, so few clinical trials related specifically
to stroke recovery are available for our patients.
The lack of clinical trials related to stroke recovery is
contrasted with an awesome explosion in our understanding
of cell death pathways, axonal regeneration, stem cells,
remyelination, and synaptogenesis. Pioneering work of
Randy Nudo and colleagues has been expanded on by a
number of stroke recovery biologists including Tim
Murphy, Michael Chopp, Eng Lo, and Tom Carmichael
who continue to leverage the best in contemporary
neuroscience to shed light on the biology of post-acute
stroke [2–6]. How can we change the current translational
trajectory to begin to harness remarkable advances in our
understanding of the biology of stroke injury and repair to
appropriate pharmacological and biological manipulations
in animals and then in humans?
First, we must begin to educate the medical and lay
communities regarding the urgency surrounding the growing
epidemic of brain disability following ischemic or hemor-
rhagic stroke. A project mentality, much like that surround-
ing the Manhattan Project, must be developed. One of the
first mandates of this project must be to rigorously define
the natural history of ischemic and hemorrhagic stroke so
that we can appropriately counsel those patients who are
likely to lead lives of long-term disability to participate in
clinical trials. It would be ideal to have blood and imaging
biomarkers that facilitate prospective identification of those
patients who are likely to do poorly [7].
The second mandate of this project will be to develop
rodent models of stroke recovery that appropriately reflect
the challenges faced by humans. While the primate models
of stroke have created enormous intellectual momentum,
widely utilized rodent models of stroke often target
behaviors that spontaneously recover. And although alter-
ing the kinetics of recovery is a tangible goal with medical
and financial benefits, it does not allow the identification of
therapeutic approaches that change the amplitude of
recovery [8]. As many stroke patients experience little to
no improvement in some functions, being able to model
persistent deficits in physiologically meaningful paradigms
(e.g., permanent and transient ischemia) is essential.
A third mandate of this project relates directly to mandate
2. Specifically, with the animal models, we need to harness
the enormous expertise that exists in behavioral neuroscience
community that historically has been used to study learning
and memory to monitor rodent behavior in ways that allow
us to define the critical biological parameters required to
restore impairments such as vision, hand movement, and
speech [9]. An untested set of assumptions are that growing
axons longer, increasing neurogenesis and increasing angio-
genesis, are primary goals in achieving recovery.
The fourth mandate of this project must be to create
infrastructures for the development of small molecule “sets”
R. R. Ratan (*)
Burke-Cornell Medical Research Institute,
785 Mamaroneck Avenue,
White Plains, NY 10605, USA
e-mail: rratan@burke.org
Transl. Stroke Res. (2010) 1:71–73
DOI 10.1007/s12975-010-0024-6that are structurally diverse but whose commonality is to
affect a single target. For example, a set of small molecules
that activate or inhibit the BDNF receptor, TrkB, would allow
one to ask whether this is a viable target for manipulation
following stroke. Genetic knockouts are valuable in defining
the selectivity of drugs for targets, but it is often difficult to
manipulate these targets using molecular tools post-injury in a
way that is clinically meaningful. Medicinal chemists must
partner with stroke biologist to facilitate rapid evaluation of
the most promising targets [10].
The fifth mandate of this project must be to create an
understanding of how the acute injury process interfaces
with brain repair and vice versa. We now know from many
studies now that starting rehabilitation too early may be
detrimental likely due to extant worsening of glutamate
dyshomeostasis after stroke [11]. It is thus important to
develop repair approaches that protect the brain. We have
dual developed several molecules that have the ability to
not only enhance repair but also to protect neurons.
Effective agents which posses protective and repair capac-
ities will have at least three important benefits: (1) they can
be used at any time after the initial ictus for protection or
repair and thus have a wide therapeutic window; (2) they
allow one to consider starting a repair agent very early
without concern that it might damage the brain; and (3)
when used as neuroprotective agents, they provide assur-
ance that neuroprotection will not foul the landscape for
repair. Along these lines, members of our Institute have
identified three viable targets to meet these lofty challenges
in vitro but are just making their way to stroke models: (1)
Inducers of arginase 1 transcription—These have the
ability induce a cassette of genes, including arginase 1 that
can reduce nitric oxide toxicity (by degrading arginine), and
also overcome barriers to regeneration by converting
arginine to polyamines [12]. The prototype of this group
is the soy isoflavone daidzein [10]. (2) Inhibitors of the
Hypoxia inducible factor prolyl hydroxylases—Inhibitors of
these enzymes have the ability to activate 70 to 100 genes
involved in adaptation to ischemia, including erythropoie-
tin, vascular endothelial growth factor, and heme-
oxgygenase that cannot only protect the brain but also
enhance neurogenesis and angiogenesis. HIF PHD inhibi-
tion appears to convert or divert the prodeath effects of HIF
activation toward survival [13]. The prototype of this group
is the iron chelator, desferoxamine. (3) Isoform selective
HDAC6 inhibitors—Brett Langley and colleagues at Burke
and Cornell showed that selective inhibitors of HDAC6 not
only have the ability to protect the brain but also enhance
the growth of axons in the presence of myelin inhibitors or
chondroitin sulfate proteoglycans. The prototype of this
group of compounds is tubastatin [14]. Testing of com-
pounds selective for each of these targets according to the
well-developed STAIR criteria is essential.
Any good project of this magnitude and impact requires
a pluralistic effort from investigators representing diverse
fields from around the world. The mandates enumerated in
this Editorial represent only a beginning, and a central
mission of this journal, Translational Stroke, is, among
other things, to catalyze consortium-driven efforts that can
move beyond incremental improvements to change thera-
peutics. I finish by respectfully challenging my colleagues
to join with me to build on these mandates to expand stroke
therapeutics to all patients, not simply the few that make it
to the hospital within 3 h of the onset of their ischemia.
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